New diabetes shot shows promise in Late-Stage trial

NCT ID NCT06777238

Ongoing Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tests an injectable drug called GZR18 in 274 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants receive either GZR18 or a placebo to see if the drug improves blood sugar levels, weight, and waist size. The trial is active but not recruiting, and results will help determine if GZR18 is a safe and effective treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR18 injection
What this could lead to: If successful, this could offer a new injectable option to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong: This is a Phase 3 trial, but results may not apply to all populations. Side effects are possible, and the drug may not prove significantly better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Beijing

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.